Mankind Pharma: Certificate under SEBI Regulations for Q3 FY26
Mankind Pharma Limited received a certificate from its RTA, KFin Technologies, for the quarter ended December 31, 2025. No share dematerialisation or rematerialisation requests were processed during this period.
This is a standard regulatory filing confirming the absence of share dematerialisation/rematerialisation requests, which is a routine procedural update and is unlikely to have a material impact on the company's stock.
The announcement is a routine compliance filing and does not contain any new financial information or significant business updates that would impact the company's stock price.
Mankind Pharma Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, to the BSE and NSE. This certificate confirms that KFin Technologies Limited, the company's Registrar and Share Transfer Agent, received no requests for dematerialisation or rematerialisation of shares during the quarter ended December 31, 2025.
The period covered by the certificate is from October 1, 2025, to December 31, 2025. The company has requested that this information be taken on record.
This is a routine compliance filing related to share transfer and dematerialisation processes.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.